IDH1/2 mutations and the other genetic lesions in genes encoding for epigenetic modifiers (DNMT3A, ASXL1, and TET2) are early events in the development of AML, like those observed in deep sequencing and single-cell studies determining clonal evolution in myeloid malignancies [11,29]. This evidence concerns the gene IDH1 and acute myeloid leukemia.